WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has announced that the US Patent and Trademark Office (USPTO) has granted a patent for its proprietary engineering platform, WuXiBody. This platform is designed to significantly enhance the developability characteristics of bispecific antibodies, marking the first time WuXiBody has received patents in the US, Japan, and China.
Launched in 2018, WuXiBody has gained global adoption due to its ability to effectively overcome common manufacturing challenges associated with bispecific antibody development. The platform is known for its high expression yield, stability, solubility, and ease of purification to homogeneity. It can also reduce development timelines by 6-18 months and significantly lower manufacturing costs compared to many other current bispecific platforms. As of December 31, 2023, there are 45 out-licensed WuXiBody projects in various stages of development, with four in Phase I clinical trials. The company anticipates two additional Investigational New Drug (IND) filings based on WuXiBody in 2024.- Flcube.com
